Published on
Onology-Induced Vulnerabilities in Cancer Treatment
I. Actionable Mutations & Targeted Therapy:
  • Concept: Sequencing identifies mutations that activate specific pathways, making them targetable with specific inhibitors ("actionable mutations").
  • Examples:
    • BRAF: Mutations in BRAF (an oncogene) in melanoma led to the development and clinical use of BRAF kinase inhibitors. Effectiveness is BRAF mutation-dependent. Rapid resistance development is a limitation.
    • HER2: HER2 overexpression makes cancers responsive to the blocking antibody trastuzumab.
    • BCR-ABL: BCR-ABL fusions in chronic myeloid leukemia (CML) are effectively targeted by imatinib and other ABL inhibitors.
II. Challenges with Loss-of-Function Mutations & Tumor Suppressors:
  • Difficulty in Restoration: Restoring lost tumor suppressor proteins via gene therapy is currently infeasible.
  • Indirect Targeting: Loss of some tumor suppressors (e.g., APC, PTEN) activates druggable pathways (Wnt, PI3 kinase).
  • Synthetic Lethality/Induced Vulnerabilities: The loss of tumor suppressors like p53 or BRCA1/2 doesn't directly reveal targetable pathways. Therefore, screens (small molecule and RNAi) are used to identify synthetic lethality or induced vulnerabilities— situations where inhibiting a specific gene or pathway is lethal only in the context of another gene already being non-functional.
III. Synthetic Lethality: A Promising but Challenging Approach:
  • Example: BRCA1/2 Deficiency & PARP Inhibitors: BRCA1/2 deficient cells (involved in DNA repair) show synthetic lethality with PARP inhibitors. PARP inhibitors target a compensatory DNA repair pathway. These cells are also sensitive to platinum-based chemotherapeutics (carboplatin, cisplatin). This demonstrates a successful example, albeit not fully translated to widespread clinical use.
IV. Clinical Translation Challenges:
  • Limited Success of Kinase Inhibitors: Few kinase inhibitors work as single agents in clinical trials, even when key pathways are inhibited.
  • Complexity of Cancer: The high mutational burden in human cancers means mutations rarely occur in isolation.
  • Tumor Microenvironment: Resistance to targeted agents can arise from both tumor cells and the surrounding stromal cells. This complexity further complicates the development of effective therapies.
Key Terms to Understand:
  • Actionable Mutation: A mutation that can be targeted with a specific drug.
  • Synthetic Lethality: The phenomenon where a combination of loss-of-function mutations in two different genes leads to cell death, while loss of function in either gene alone does not.
  • Induced Vulnerabilities: Similar to synthetic lethality, but might not involve two distinct gene losses.
  • Oncogene: A gene that can, when mutated or overexpressed, contribute to the development of cancer.
  • Tumor Suppressor Gene: A gene that normally functions to prevent cancer. Loss of function in tumor suppressor genes increases cancer risk.
  • PARP (Poly(ADP-ribose) polymerase): An enzyme involved in DNA repair.




Picture
Published on
Oncology- Multistep Carcinogenesis
I. The Driver Mutation Concept:
  • Origin: The idea of "driver mutations" emerged from sequencing studies, but the observation of frequent specific mutations in certain cancers predates this by over 20 years. These mutations are not random; they play a crucial role in initiating and driving cancer development.
  • Initiating Events: Certain mutations are highly prevalent in specific cancers, suggesting they are initiating events. Examples include:
    • APC: Frequently mutated in colorectal cancer (78-80%). Leads to benign polyps.
    • KRAS: Frequently mutated in pancreatic ductal adenocarcinomas (up to 95%). Leads to pre-malignant PanINs.
    • BRAF: Frequently mutated in benign nevi (skin moles), precursors to melanoma.
These initiating mutations create benign lesions, which alone do not progress to cancer. Malignancy requires further mutations.
II. Progression from Benign to Malignant:
  • Second Hits and Beyond: Progression from benign lesions to malignant tumors requires the acquisition of additional mutations ("second hits" and subsequent hits). These are not random; they often act in response to the effects of the initiating oncogene.
  • Example: Overcoming Senescence: KRAS and BRAF mutations often induce cellular senescence (growth arrest), preventing further progression. However, mutations in genes that counteract senescence, such as p16, PTEN, and p53, allow the tumor to bypass this growth arrest and progress to malignancy.
III. Colon Cancer as a Model:
  • Multistep Progression: The multistep model is best exemplified in colon cancer. Following the initiating APC mutation, further mutations frequently occur in:
    • KRAS
    • TP53
    • Genes in the TGFβ pathway
    • Genes in the PI3 kinase pathway
  • Pathway Involvement: Most colon cancers show mutations in at least three of these five pathways. While other mutations exist outside these pathways, their roles in tumor progression are less well understood and require further research.
IV. Key Concepts to Remember:
  • Driver vs. Passenger Mutations: Driver mutations are functionally important for tumor initiation and progression. Passenger mutations have no significant effect.
  • Multistep Nature of Carcinogenesis: Cancer development is a multi-step process requiring accumulation of multiple mutations over time.
  • Context-Specific Mutations: The importance of a specific mutation depends on the context of other mutations present within the cell.
  • Therapeutic Implications: Understanding the specific driver mutations in a cancer helps to select targeted therapies.
Picture
Published on
Oncology-Genetic Predisposition to Cancer
I. Increased Cancer Risk in Families:
  • Moderate Increase: Epidemiological studies show a 2-3 times higher cancer risk among first-degree relatives of cancer patients. This isn't always due to inherited gene alterations; shared environmental factors or increased susceptibility to carcinogens also play a role.
II. Recognizing Familial Cancers:
Familial cancers may be indicated by several factors:
  • Rare, Genetic Cancers: Examples include bilateral retinoblastoma.
  • Associated Phenotypic Features: These are observable physical characteristics associated with specific genetic syndromes, such as:
    • FAP (Familial Adenomatous Polyposis): Multiple polyps.
    • Peutz-Jeghers Syndrome: Mucosal pigmentation.
    • DNA Repair Disorders: Chromosome breakage.
  • Family History Clues: These suggest a higher likelihood of inherited predisposition:
    • Early Onset: Cancer diagnosed at an unusually young age.
    • Multiple or Bilateral Tumors: More than one tumor, or tumors on both sides of the body (e.g., both breasts).
    • Familial Clustering: Multiple family members with the same or related cancers (e.g., breast and ovarian cancer; colon and uterine cancer).
III. Suspicious Family Histories: The following family histories warrant further investigation (referral to clinical genetics):
  • Three or more close relatives (same side of family) with the same common cancer (or related cancers).
  • Two or more close relatives (same side of family) with the same common cancer (or related cancers), with at least one diagnosis before age 50.
  • One close relative with early-onset cancer (e.g., breast cancer <40, bowel cancer <45).< />pan>
  • One close relative with multiple primary cancers.
  • Two or more relatives with the same uncommon cancer (e.g., sarcoma, glioma, pancreatic cancer).
IV. Clinical Evaluation and Genetic Testing:
  • Clinical Examination: May reveal specific features of genetic syndromes like Cowden syndrome, Gorlin syndrome, or neurofibromatosis. Know the characteristic features of each.
  • Genetic Testing: Possible only when a causative germline mutation can be identified in a blood sample from an affected relative. Often, testing isn't possible due to:
    • Lack of a suspected mutation in known predisposition genes.
    • Unavailability of samples from affected relatives.
    • Failure to identify the causative mutation in relevant genes.
  • Cancer Surveillance: May be arranged for at-risk relatives, but effectiveness is often unproven. Participation in relevant clinical trials is encouraged.
V. Key Terms and Concepts to Master:
  • Germline mutation: A mutation present in an organism's germ cells (sperm or eggs), which can be passed on to offspring.
  • Phenotypic features: Observable physical characteristics.
  • Familial clustering: The occurrence of the same or related cancers in multiple members of a family.
  • Early-onset cancer: Cancer diagnosed at a younger age than typically expected.
  • Bilateral tumors: Tumors occurring on both sides of the body.
  • Clinical genetics services: Specialized medical services that evaluate and manage inherited conditions, including cancer predisposition.
Picture
Published on
Oncology-Predictive Genetic Testing
I. Predictive Genetic Testing: The Basics
  • Purpose: To determine if a family member has inherited a specific gene mutation known to increase cancer risk. This is offered after a mutation is identified in a family member and they consent to share their results.
  • Process: Typically conducted through a clinical genetics service, preceded by genetic counseling to fully explain the implications.
  • Result Interpretation:
    • Positive Result: Does not guarantee cancer development, but informs surveillance needs and risk-reducing surgery decisions. It also clarifies risks for future generations.
    • Negative Result: Does not guarantee against cancer development. It simply means the specific familial mutation wasn't found; a genetic predisposition may still exist.
  • Considerations: Psychological distress for the individual being tested and their family should be anticipated and addressed. Potential insurance implications are also a concern, although guidelines exist to mitigate these in many regions.
II. Implications for the Affected Individual (Whose Sample Initiates Testing)
The focus on predictive testing often overlooks the implications for the affected individual whose genetic material initiates the testing process. These implications include:
  • Negative Test Results: A negative result (no mutation identified) does not rule out a genetic predisposition in the family. It simply means the specific mutation causing cancer in the family hasn't been found yet. More research may be needed to discover the underlying genetic cause.
  • Uncertain Test Results: Sometimes a "sequence change" is found but its significance (benign or pathogenic) is unclear. Further testing is often required for clarification.
  • Positive Test Results: A positive result can lead to:
    • Psychological Distress: Including guilt over potentially passing the mutation to family members, especially children.
    • Increased Cancer Risks: Identifying a specific mutation might reveal a heightened risk for other cancers (e.g., ovarian cancer with a BRCA1 breast cancer mutation) not initially apparent from the family history (metachronous cancers or cancers at associated sites).
III. Key Concepts to Remember
  • No guarantees: Neither positive nor negative predictive genetic testing results guarantee the development or absence of cancer.
  • Psychological impact: The emotional consequences for the tested individual and their family must be carefully considered.
  • Further investigation: Negative or unclear results may require additional testing or research.
  • Broader implications: Testing results can significantly impact medical decisions, family planning, and insurance


Picture
Published on
Oncology -Bowel Cancer Family History

I. Recognizable Syndromes & Polyposis:
  • Increased risk can stem from identifiable syndromes characterized by polyp presence.
  • Genetic testing is effective in identifying causative mutations in most cases.
  • Key Syndromes & Polyposis:
    • FAP (Familial Adenomatous Polyposis): Classically >100 bowel polyps. Autosomal dominant; mutations in the same gene as attenuated FAP, differing in mutation site and phenotype.
    • Attenuated FAP: <100 polyps, later onset, high bowel cancer risk, and risk for upper gi malignancy. autosomal dominant, same gene as fap.< />pan>
    • MYH-associated polyposis: Autosomal recessive; predisposition to adenomatous bowel polyps; often presents with sibling history of bowel cancer. Testing focuses on two common MYH gene mutations.
II. Hereditary Non-Polyposis Colon Cancer (HNPCC) / Lynch Syndrome:
  • More common than recognizable syndromes.
  • Characterized by: Familial aggregation of bowel cancer with fewer polyps.
  • Genetic basis: Primarily due to mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2). Defective DNA repair leads to increased mutation rates and faster cancer progression.
  • Microsatellite instability (MSI): A laboratory finding in tumor tissue indicating a likely mismatch repair gene mutation. Used in risk assessment.
III. Risk Assessment & Management:
  • Family History Assessment: Crucial for determining risk level. Factors considered:
    • Low Risk: One affected relative >45 years; two relatives >55 years or on different sides of the family. Reassurance may be appropriate.
    • Moderate Risk: One relative <45 years; two relatives (one <55 years); three affected at any age. tumor tissue analysis is warranted.< />pan>
    • High Risk (Amsterdam Criteria): At least three individuals with bowel cancer across two generations; at least one affected individual <50 years; familial polyposis excluded.< />pan>
  • Tumor Tissue Analysis (for moderate risk):
    • MSI testing: Identifies potential mismatch repair gene mutations.
    • Loss of expression of mismatch repair proteins: Helps determine which gene to analyze first.
    • BRAF V600E mutation testing: Its presence suggests sporadic cancer (not germline mutation) and hypermethylation.
  • Genetic Testing: Offered if mutation suspected (moderate or high risk). Guides surveillance strategies.
  • Surveillance Strategies:
    • Moderate risk: Colonoscopy at presentation and at age 55.
    • High risk (known gene carriers): 2-yearly colonoscopies from age 25 or 35 (depending on family history).
  • Additional Considerations: Families with known mismatch repair gene mutations should also consider surveillance for endometrial cancer (high risk) and other cancers (e.g., gastric cancer in those >50).
IV. Key Terms & Concepts:
  • Autosomal Dominant: One affected allele leads to the condition.
  • Autosomal Recessive: Two affected alleles are required.
  • Mismatch Repair Genes: Genes involved in DNA repair; mutations increase cancer risk.
  • Microsatellite Instability (MSI): A marker of mismatch repair deficiency.
  • Germline Mutation: A mutation present in all cells of the body, inherited from parents.
  • Somatic Mutation: A mutation acquired during an individual's lifetime, not heritable.
Picture
Published on
Oncology-Diagnosis and Staging of Malignant Disease
This guide summarizes techniques for diagnosing and staging malignant diseases, emphasizing best practices and potential pitfalls.
I. Improving Diagnostic Accuracy:
  • Advanced Imaging: Ultrasound, CT, and MRI significantly improve localization and staging, guiding more accurate biopsies.
  • Biopsy Techniques:
    • Fine Needle Aspiration (FNA) Cytology: Less invasive, but may yield insufficient tissue for complete analysis. Lower risk of tumor seeding than core biopsy.
    • Core Biopsy: Preferred for adequate tissue architecture and receptor status assessment (e.g., breast cancer). Higher risk of tumor seeding than FNA.
    • Endoscopic Techniques (including EUS): Allow tissue sampling (cytology, biopsy, brushings) for histopathological analysis, particularly useful for cystic lesions (e.g., pancreas).
  • Tumor Seeding: A significant risk, especially with core biopsies and certain tumor types (e.g., soft tissue sarcomas). Needle track placement should be planned with the surgeon to allow excision during definitive surgery. Ablation of the biopsy track may reduce risk.
  • Transcoelomic Biopsies: Generally avoided unless discussed in an MDT (Multidisciplinary Team) appropriate to the suspected tumor type, and only when radiological diagnosis is insufficient and surgical resection isn't a curative option (e.g., colorectal liver metastases).
II. Biopsy Procedures and Considerations:
  • Cytology Sample Examination: Requires experienced cytopathologists.
  • Incisional Biopsy: Should not compromise future definitive surgery.
  • Excisional Biopsy: Ideally performed by the surgeon undertaking definitive surgery, particularly crucial for melanoma (2mm margin recommended for suspicious lesions). Margin controversy exists depending on melanoma depth.
  • Specialized Staining/Analysis: Close surgeon-pathologist collaboration is vital when specialized staining (e.g., immunohistochemistry), electron microscopy, or cytogenetic analyses are needed (e.g., lymph node excision for lymphoma – tissue should be sent fresh).
III. Laparoscopy in Diagnosis and Staging:
  • Laparoscopic Biopsy: Valuable for accessing areas difficult for image-directed biopsy (e.g., mesentery, retroperitoneal space).
  • Peritoneal Washing Cytology: Used in staging upper abdominal malignancies. 500mL of warm saline is instilled, agitated, and aspirated for cytological analysis. Detection of tumor cells indicates poor prognosis.
  • Intraoperative Ultrasonography: Allows detection and biopsy (even treatment via laparoscopic ablation) of lesions, including those <1cm, in solid organs (e.g., liver). doppler ultrasound aids avoiding vascular structures.< />pan>
IV. Key Points to Remember:
  • The choice of biopsy technique depends on the suspected diagnosis, tumor type, and access to resources.
  • Minimizing the risk of tumor seeding is crucial, requiring careful planning and potentially preventative measures.
  • Multidisciplinary collaboration between radiologists, pathologists, surgeons, and other specialists is essential for optimal diagnosis and staging.
  • Advanced imaging techniques guide biopsy procedures, increasing accuracy.
  • Laparoscopy offers valuable diagnostic and staging capabilities, particularly for challenging locations.​
Picture
Published on
Oncology-Oncology Surgical Principles
This guide summarizes key concepts regarding the surgical management of solid tumors. Focus on understanding the nuances, not just memorizing facts.
I. General Principles of Surgical Oncology:
  • Surgery's Central Role: Surgery remains the primary treatment and offers the best chance of cure for most solid tumors, particularly those localized. However, advancements allow for long-term survival even in some metastatic cases.
  • Five Main Surgical Roles: Grasp the distinct roles surgery plays:
    • Diagnosis & Staging: Surgical biopsy for definitive diagnosis and assessing tumor extent.
    • Curative Surgery: Removal of the entire tumor with the aim of a complete cure.
    • Palliative Surgery: To alleviate symptoms and improve quality of life, not necessarily to cure.
    • Surgery for Metastatic Disease: Addressing spread of cancer, e.g., removing metastases.
    • Prophylactic Surgery: Preventive surgery to reduce cancer risk (e.g., mastectomy in high-risk individuals).
  • Tumor Biology is Crucial: Surgical planning necessitates a deep understanding of the tumor's biology and behavior. Failure to account for this leads to poor outcomes.
II. Tumor Spread & Implications for Surgery:
  • Three Main Spread Mechanisms: Understand the differences in spread and their surgical implications.
    • Direct Infiltration: Tumor grows into adjacent tissues.
    • Lymphatic Spread: Cancer cells travel through the lymphatic system.
    • Blood-borne Spread (Hematogenous): Cancer cells spread via the bloodstream.
  • Variability in Spread Patterns: Most cancers utilize all three mechanisms, but to varying degrees. Recognize these examples:
    • Breast & Colorectal Cancers: Primarily lymphatic and hematogenous spread.
    • Upper GI & Upper Airway Cancers: Predominantly lymphatic spread.
    • Thyroid Cancer (Papillary vs. Follicular): Illustrates how even cancers of the same origin can spread differently (lymphatic vs. hematogenous, respectively). This directly impacts surgical approach.
III. Tumor-Host Interaction:
  • Inflammation's Importance: The interplay between the tumor and the host's inflammatory response is increasingly recognized as crucial for predicting outcome and guiding adjuvant therapy decisions. This is an area of active research.​



Picture
Published on
Oncology- Multidisciplinary Approach to Cancer Management
This guide summarizes the complexities of cancer treatment and the crucial role of multidisciplinary teams (MDTs).
I. Core Concept: The Need for a Multidisciplinary Approach
Cancer treatment is highly complex, requiring diverse expertise beyond the scope of any single clinician. This necessitates a multidisciplinary team (MDT) approach. No one specialist possesses the full range of skills for diagnosis, staging, treatment (surgery, chemotherapy, radiotherapy, hormonal therapy), and long-term care needed across various cancer types.
II. Key Components of Cancer Management:
  • Diagnosis & Staging: Initial assessment involves various diagnostic tests (pathological confirmation and imaging) to determine the cancer type and extent of its spread.
  • Surgical Intervention: Surgery is frequently a primary treatment modality.
  • Adjuvant Therapies: These therapies complement surgery, including chemotherapy, radiotherapy, and hormonal therapy. These are often used pre- or post-operatively.
  • Palliative Care: This specialized care focuses on improving quality of life for patients with advanced cancer. It may be integrated at various stages of the illness.
III. The Role of the Multidisciplinary Team (MDT):
MDTs are composed of a range of healthcare professionals, including but not limited to: surgeons, oncologists, radiotherapists, nurses, physiotherapists, stoma nurses, counselors, and palliative care specialists. The specific composition varies depending on the institution and the type of cancer being treated.
The MDT's responsibilities encompass several key areas:
  • Treatment Planning: Collaborative decision-making regarding diagnostic procedures, primary treatment strategies (including surgery, radiotherapy and chemotherapy), and adjuvant therapies.
  • Patient Preparation: Physically and psychologically preparing patients for treatment and follow-up. This includes providing comprehensive information about the treatment process, prognosis, potential side effects, and any necessary post-treatment care (e.g., stoma care).
  • Treatment Delivery: Efficient coordination and execution of surgery, radiotherapy, and chemotherapy.
  • Rehabilitation & Follow-up: Providing rehabilitation services and ongoing monitoring post-treatment.
  • Palliative Care Integration: Seamless transition to palliative care when appropriate.
  • Clinical Trial Participation: Encouraging patients to consider participating in relevant clinical trials.
  • Quality Assurance: The MDT actively audits its procedures and performance to ensure continuous improvement and benchmarking against other teams.​
IV. Benefits of the MDT Approach:
Studies show MDT management leads to improved patient outcomes:
  • Increased Survival Rates: Improved survival times are a key benefit.
  • Enhanced Quality of Life (QoL): Patients experience improvements in physical functioning, psychological well-being, and cosmetic outcomes, contributing to a better overall QoL.
Picture
Published on
Oncology-Low-Risk Alleles and Cancer Risk
I. Key Concepts:
  • Genome-Wide Association Studies (GWAS): Large-scale studies that scan the entire genome to identify genetic variations (SNPs) associated with a particular disease. They're crucial for identifying low-risk alleles.
  • Single Nucleotide Polymorphisms (SNPs): Single base-pair variations in DNA sequence. These are the most common type of genetic variation and can occur anywhere in the genome, including promoter regions (affecting gene expression) and introns (non-coding regions).
  • Low-risk alleles: SNPs identified through GWAS that individually contribute a small increase in disease risk. Crucially, their cumulative effect can significantly impact disease development.
  • Oncogenes and Tumor Suppressor Genes: Genes that, when mutated, can contribute to cancer development. Oncogenes promote cell growth, while tumor suppressor genes inhibit it.
  • Genetically Engineered Mouse Models (GEMMs): Mice genetically modified to mimic human diseases, allowing researchers to study disease mechanisms and test therapeutic strategies.
II. Low-Risk Alleles and Colon Cancer:
The text focuses on the discovery of low-risk alleles for colon cancer via GWAS. These SNPs are frequently located in:
  • Promoter regions: Affecting gene expression levels of key genes.
  • Introns: Although not directly coding for proteins, introns can impact gene expression through regulatory mechanisms.
Importantly, these SNPs are often found within established cancer pathways:
  • MYC oncogene: An oncogene whose over-expression is implicated in many cancers.
  • Bone Morphogenetic Protein (BMP) signaling pathway: A crucial pathway involved in cell growth and differentiation; disruption can lead to uncontrolled cell growth.
III. Significance of Low-Risk Alleles:
The use of GEMMs is crucial in demonstrating the impact of these seemingly insignificant low-risk alleles. Manipulating these SNPs in GEMMs has shown profound effects on tumor development, suggesting that even small genetic variations can contribute substantially to cancer initiation and progression.
IV. Clinical Implications:
The discovery of disease-associated SNPs, even low-risk ones, holds important clinical implications. Individuals carrying these SNPs may require:
  • Increased screening: More frequent colonoscopies or other screening methods to detect cancer early.
Picture
Published on
Oncology-Curative Surgery
This study guide summarizes the provided text on curative cancer surgery, focusing on key concepts for improved understanding and retention.
I. Factors Influencing Long-Term Outcomes:
  • Tumor Type and Stage: The most significant determinants of long-term survival after cancer surgery. Earlier detection (due to screening and awareness) improves outcomes for cancers like breast and cervical cancer.
  • Surgical and Anesthetic Advances: Allow for more extensive resections with reduced morbidity and mortality, improving functional outcomes (e.g., limb-preserving surgery). However, limitations remain, especially in CNS tumors due to vital structures.
  • 5-Year Survival Rates: Vary drastically across cancer types. High survival rates are seen in breast cancer (>80%) and large bowel cancer (~70% in the US). However, pancreatic, gastric, and lung cancers have significantly lower 5-year survival rates (<10%, <10%, and 15%, respectively).< />pan>
  • Microscopically Negative Margins: Achieving clear margins (absence of cancerous cells at the resection site) is crucial for long-term survival. This necessitates close collaboration between surgeons and pathologists.
II. Margin Requirements and Controversies:
  • Breast Cancer: Wide local excision requires 0.5-1cm clear margins, often followed by radiotherapy. However, some surgeons accept smaller margins (a few mm), leading to ongoing debate.
  • Colorectal Cancer: Requires a 5cm proximal and 2cm distal margin for adequate clearance. Maintaining these margins is particularly important during the learning curve of laparoscopic procedures.
  • Rectal Cancer: Total mesorectal excision is essential to prevent pelvic recurrence. Specialization in rectal cancer surgery significantly improves outcomes.
  • Multifocal Cancers (e.g., Papillary Thyroid Cancer): May necessitate wider resections (e.g., total thyroidectomy) to remove all tumor foci. Controversy exists, with total lobectomy sometimes sufficient.
  • High-Volume Centers and Specialists: Growing evidence suggests that major oncological surgeries should be performed by specialists in high-volume centers (e.g., rectal, esophageal, gastric, and pancreatic cancers) to optimize outcomes.
III. Laparoscopic Techniques:
  • Early Advantages: Laparoscopic surgery showed promise in reducing postoperative morbidity and accelerating recovery.
  • Oncological Adequacy Concerns: Initial concerns regarding achieving adequate oncological clearance were addressed by long-term follow-up studies.
  • Current Evidence: Long-term studies in colorectal, renal, prostatic, and gynecological cancers demonstrate comparable negative margin rates, lymph node yields, and disease-free survival (DFS) to open surgery. Data for gastric, esophageal, pancreatic, and hepatic malignancies are still emerging.
Key Terms:
  • Morbidity: Illness or impairment resulting from disease or treatment.
  • Mortality: Death rate.
  • Resection: Surgical removal of a part of an organ or structure.
  • Margins: The tissue surrounding a tumor that is removed during surgery.
  • Disease-Free Survival (DFS): The length of time after treatment that a person lives without any signs or symptoms of the disease.
  • Overall Survival (OS): The length of time after diagnosis that a person lives.
  • CNS: Central nervous system.
Picture

Kembara Xtra 

Facts about medicine and its subtopic such as anatomy, physiology, biochemistry, pharmacology, medicine, pediatrics, psychiatry, obstetrics and gynecology and surgery.